keyword
https://read.qxmd.com/read/38455369/sequential-neoadjuvant-chemotherapy-using-pegylated-liposomal-doxorubicin-and-cyclophosphamide-followed-by-taxanes-with-complete-trastuzumab-and-pertuzumab-treatment-for-her2-positive-breast-cancer-a-phase-ii-single-arm-study
#21
JOURNAL ARTICLE
Yaping Yang, Liang Jin, Yudong Li, Nanyan Rao, Chang Gong, Shunrong Li, Jiannan Wu, Jinghua Zhao, Linxiaoxiao Ding, Fengxia Gan, Jun Zhang, Ruifa Feng, Zhenzhen Liu, Qiang Liu
OBJECTIVE: Despite cardiotoxicity overlap, the trastuzumab/pertuzumab and anthracycline combination remains crucial due to significant benefits. Pegylated liposomal doxorubicin (PLD), a less cardiotoxic anthracycline, was evaluated for efficacy and cardiac safety when combined with cyclophosphamide and followed by taxanes with trastuzumab/pertuzumab in human epidermal growth factor receptor-2 (HER2)-positive early breast cancer (BC). METHODS: In this multicenter, phase II study, patients with confirmed HER2-positive early BC received four cycles of PLD (30-35 mg/m2 ) and cyclophosphamide (600 mg/m2 ), followed by four cycles of taxanes (docetaxel, 90-100 mg/m2 or nab-paclitaxel, 260 mg/m2 ), concomitant with eight cycles of trastuzumab (8 mg/kg loading dose, then 6 mg/kg) and pertuzumab (840 mg loading dose, then 420 mg) every 3 weeks...
February 29, 2024: Chinese Journal of Cancer Research
https://read.qxmd.com/read/38453739/a-prospective-comparison-study-utilizing-patient-reported-outcomes-of-taxane-related-peripheral-neuropathy-between-nab-paclitaxel-and-standard-paclitaxel-in-patients-with-breast-cancer
#22
JOURNAL ARTICLE
Kumiko Kida, Akimitsu Yamada, Kazuhiro Shimada, Kazutaka Narui, Sadatoshi Sugae, Daisuke Shimizu, Takako Doi, Mari Oba, Itaru Endo, Takashi Ishikawa
UNLABELLED: BACKGROUND: Characteristics of taxane-induced peripheral neuropathy (PN) could be different between paclitaxel and nab-paclitaxel. The purpose of this prospective observational multicenter cohort study was to compare tri-weekly nab-paclitaxel to weekly standard paclitaxel regarding the severity, onset and recovery of sensory and motor PN in patients with breast cancer. METHODS: Patients with histologically confirmed breast cancer who were scheduled to receive standard weekly paclitaxel (80 mg/m2 ) or tri-weekly nab-paclitaxel (260 mg/m2 ) at institutions in our multicenter group were eligible for this study...
March 8, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38450375/safety-and-possible-anti-inflammatory-effect-of-paclitaxel-associated-with-ldl-like-nanoparticles-lde-in-patients-with-chronic-coronary-artery-disease-a-double-blind-placebo-controlled-pilot-study
#23
JOURNAL ARTICLE
Lucas Lage Marinho, Fabiana Hanna Rached, Aleksandra Tiemi Morikawa, Thauany Martins Tavoni, Ana Paula Toniello Cardoso, Roberto Vitor Almeida Torres, Antonildes Nascimento Assuncao, Carlos Vicente Serrano, Cesar Higa Nomura, Raul Cavalcante Maranhão
INTRODUCTION: Studies in cholesterol-fed rabbits showed that anti-proliferative chemotherapeutic agents such as paclitaxel associated with solid lipid nanoparticles (LDE) have marked anti-atherosclerotic effects. In addition, association with LDE nearly abolishes paclitaxel toxicity. We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled pilot study in patients with multi-vessel chronic coronary artery disease...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38449794/efficacy-of-nab%C3%A2-paclitaxel-vs-gemcitabine-in-combination-with-s%C3%A2-1-for-advanced-pancreatic-cancer-a-multicenter-phase-ii-randomized-trial
#24
JOURNAL ARTICLE
Xi Guo, Wenhui Lou, Yaolin Xu, Rongyuan Zhuang, Lie Yao, Junwei Wu, Deliang Fu, Jun Zhang, Jing Liu, Yefei Rong, Dayong Jin, Wenchuan Wu, Xuefeng Xu, Yuan Ji, Lili Wu, Minzhi Lv, Xiuzhong Yao, Xiaowei Liu, Dansong Wang, Tiantao Kuang, Liang Liu, Wenquan Wang, Tianshu Liu, Yuhong Zhou
Patients with advanced pancreatic cancer (PC) need a cost-effective treatment regimen. The present study was designed to compare the efficacy and safety of nab-paclitaxel plus S-1 (AS) and gemcitabine plus S-1 (GS) regimens in patients with chemotherapy-naïve advanced PC. In this open-label, multicenter, randomized study named AvGmPC, eligible patients with chemotherapy-naïve advanced PC were randomly assigned (1:1) to receive AS (125 mg/m2 nab-paclitaxel, days 1 and 8; 80-120 mg S-1, days 1-14) or GS (1,000 mg/m2 gemcitabine, days 1 and 8; 80-120 mg S-1, days 1-14)...
April 2024: Oncology Letters
https://read.qxmd.com/read/38447660/establishment-of-a-patient-specific-avatar-organoid-model-derived-from-endoscopic-ultrasonography-guided-fine-needle-biopsy-for-timely-clinical-application-in-pancreatic-ductal-adenocarcinoma
#25
JOURNAL ARTICLE
Hyemin Kim, Jinho Jang, Jin Ho Choi, Joo Hye Song, Su Hyun Lee, Jiho Park, Si Kyong Ryoo, Eun Mi Lee, Hyoung-Oh Jeong, Seunghoon Kim, Se-Hoon Lee, Kwang Hyuck Lee, Kyu Taek Lee, Kyoung Mee Kim, Kee-Taek Jang, Hyunsook Lee, Semin Lee, Jong Kyun Lee, Joo Kyung Park
BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate among tumors. At the time of diagnosis, over 80 percent of PDACs are considered surgically unresectable, and there is an unmet need for treatment options in these inoperable PDACs. The study aimed to establish a patient-derived organoid (PDO) platform from endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) collected at diagnosis and to determine its clinical applicability for the timely treatment of unresectable PDAC...
March 4, 2024: Gastrointestinal Endoscopy
https://read.qxmd.com/read/38444861/dendritic-cell-vaccination-combined-with-carboplatin-paclitaxel-for-metastatic-endometrial-cancer-patients-results-of-a-phase-i-ii-trial
#26
JOURNAL ARTICLE
Bouke J Koeneman, Gerty Schreibelt, Mark A J Gorris, Simone Hins-de Bree, Harm Westdorp, Petronella B Ottevanger, I Jolanda M de Vries
BACKGROUND: Metastatic endometrial cancer (mEC) continues to have a poor prognosis despite the introduction of several novel therapies including immune checkpoints inhibitors. Dendritic cell (DC) vaccination is known to be a safe immunotherapeutic modality that can induce immunological and clinical responses in patients with solid tumors. Platinum-based chemotherapy is known to act synergistically with immunotherapy by selectively depleting suppressive immune cells. Therefore, we investigated the immunological efficacy of combined chemoimmunotherapy with an autologous DC vaccine and carboplatin/paclitaxel chemotherapy...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38422895/incorporation-of-anti-pd1-or-anti-pd-l1-agents-to-platinum-based-chemotherapy-for-the-primary-treatment-of-advanced-or-recurrent-endometrial-cancer-a-meta-analysis
#27
REVIEW
Michele Bartoletti, Marcella Montico, Domenica Lorusso, Roberta Mazzeo, Ana Oaknin, Lucia Musacchio, Giovanni Scambia, Fabio Puglisi, Sandro Pignata
IMPORTANCE: Various randomized trials have explored the efficacy of combining immune checkpoint inhibitors (ICIs) with first-line chemotherapy in advanced endometrial cancer. We aimed to summarize available data and clarify the benefit of adding immunotherapy according to the DNA mismatch repair status (deficient, dMMR or proficient, pMMR) and the specific type of agent used (anti-PD1 or anti-PD-L1). OBJECTIVE: To assess whether the addition of ICIs to standard platinum-based chemotherapy enhances progression-free survival (PFS) for patients with advanced endometrial cancer both overall and based on DNA mismatch repair status...
February 27, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38413246/artemis-a-multicenter-open-label-single-arm-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-first-line-carboplatin-paclitaxel-lenvatinib-pembrolizumab-combination-for-previously-untreated-advanced-or-recurrent-thymic-carcinomas
#28
JOURNAL ARTICLE
Yusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, Yoko Tsukita, Shuji Murakami, Yukio Hosomi, Yuichi Tambo, Yoshihito Kogure, Hiroshige Yoshioka, Motohiro Tamiya, Kiichiro Ninomiya, Eiji Iwama
BACKGROUND: Thymic carcinoma is a rare cancer with an aggressive clinical presentation and no organotypic symptoms. Despite using platinum-based chemotherapy as first-line treatment, the prognosis remains poor, necessitating a novel therapeutic strategy. METHODS: The artemis trial is a Phase II, single-arm, multicenter study designed to evaluate the efficacy and safety of carboplatin, paclitaxel, lenvatinib, and pembrolizumab as first-line chemotherapy for patients with advanced or recurrent thymic carcinoma...
February 8, 2024: Clinical Lung Cancer
https://read.qxmd.com/read/38408999/a-phase-1b-study-of-zilovertamab-in-combination-with-paclitaxel-for-locally-advanced-unresectable-or-metastatic-her2-negative-breast-cancer
#29
JOURNAL ARTICLE
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molinolo, Betty Cabrera, James B Breitmeyer, George F Widhopf, Karen Messer, Catriona Jamieson, Thomas J Kipps, Barbara A Parker
BACKGROUND: Zilovertamab is a humanized monoclonal antibody targeting ROR1, an onco-embryonic antigen expressed by malignant cells of a variety of solid tumors, including breast cancer. A prior phase 1 study showed that zilovertamab was well tolerated and effective in inhibiting ROR1-signaling, which leads to activation of ERK1/2, NF-κB, and NRF2 target genes. This phase 1b study evaluated the safety and tolerability of zilovertamab with paclitaxel in patients with advanced breast cancer...
February 26, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38389459/minimal-invasive-treatment-of-urethral-strictures-an-experimental-study-of-the-effect-of-paclitaxel-coated-balloons-in-the-wall-of-strictured-rabbit-s-urethra
#30
JOURNAL ARTICLE
Konstantinos Pagonis, Angelis Peteinaris, Constantinos Adamou, Vasileios Tatanis, Athanasios Vagionis, Anastasios Natsos, Mohammed Obaidat, Solon Faitatziadis, Evangelos Liatsikos, Panagiotis Kallidonis
PURPOSE: The aim of this study is the evaluation of the distribution of Paclitaxel (PTX) released by a coated balloon in the layers of rabbit's urethra. METHODS: 18 rabbits were included. A Laser Device was used for the stricture formation. After two weeks, dilation of the strictured urethra was performed by using Advance 35LP PTA balloons and Advance 18 PTX PTA balloons. The experimental models were divided into 3 groups. The group Α included two rabbits without any intervention except for the stenosis procedure...
February 22, 2024: Archivio Italiano di Urologia, Andrologia
https://read.qxmd.com/read/38389369/mri-plain-scan-a-tool-in-the-management-of-cervical-cancer-during-pregnancy
#31
JOURNAL ARTICLE
Feng Gao, Ting Qian, Minghua Sun, Yuanyuan Lu, Jiejun Cheng, Le Fu
OBJECTIVE: The purpose of this study was to assess the diagnostic value of magnetic resonance imaging (MRI) in staging and treatment of cervical cancer in pregnancy, and to evaluate the benefit of apparent diffusion coefficient (ADC) during neoadjuvant chemotherapy management. MATERIALS AND METHODS: This was a retrospective cohort study. Patients were divided into two groups according to the stage of cervical cancer. The mean term of pregnancy at the time of the diagnosis was the early second trimester (range 10-27 weeks) and the median age was 33 years (range 26-40 years)...
2024: Current medical imaging
https://read.qxmd.com/read/38378241/first-in-human-experience-of-sirolimus-coated-balloon-for-symptomatic-intracranial-artery-stenosis
#32
JOURNAL ARTICLE
Jichang Luo, Renjie Yang, Tao Wang, Jian Chen, Xia Lu, Bin Yang, Peng Gao, Yabing Wang, Yanfei Chen, Adam A Dmytriw, Jiamin Zheng, Robert W Regenhardt, Zheng Li, Han Xu, Yan Ma, Jonathon Zhao, Liqun Jiao
BACKGROUND: The drug coated balloon is a promising endovascular therapy for intracranial atherosclerosis (ICAS), potentially combining the advantages of primary angioplasty and antiproliferative drugs. Previous studies have focused on the paclitaxel coated balloon, revealing promising outcomes in the treatment of ICAS, while concerns about the neurotoxicity of paclitaxel were reported. Sirolimus was shown to have less neurotoxicity in the canine cerebral vasculature. The feasibility and safety of a sirolimus coated balloon (SCB) for ICAS have never been evaluated in humans...
February 20, 2024: Journal of Neurointerventional Surgery
https://read.qxmd.com/read/38373832/feasibility-of-intraoperative-radiotherapy-tumor-bed-boost-in-patients-with-breast-cancer-after-neoadjuvant-chemotherapy
#33
JOURNAL ARTICLE
Gowoon Yang, Jun Won Kim, Ik Jae Lee, Joon Jeong, Sung Gwe Ahn, Soong June Bae, Jee Hung Kim, Yeona Cho
PURPOSE: This study aimed to assess the feasibility and safety of administering intraoperative radiotherapy (IORT) as a boost during breast-conserving surgery (BCS) following neoadjuvant chemotherapy for patients at high risk of breast cancer recurrence. MATERIALS AND METHODS: Patients who underwent neoadjuvant chemotherapy received a single 20-Gy dose of IORT during BCS, followed by external beam radiotherapy 4-6 weeks after surgery. RESULTS: The median follow-up duration was 31...
March 2024: Yonsei Medical Journal
https://read.qxmd.com/read/38370796/intermittent-energy-restriction-inhibits-tumor-growth-and-enhances-paclitaxel-response-in-a-transgenic-mouse-model-of-endometrial-cancer
#34
Ziyi Zhao, Jiandong Wang, Weimin Kong, Ziwei Fang, Michael Coleman, Ginger Milne, Wesley C Burkett, Meredith A Newton, Douglas Lee, Beor Deng, Xiaochang Shen, Hongyan Suo, Wenchuan Sun, Stephen Hursting, Chunxiao Zhou, Victoria L Bae-Jump
OBJECTIVE: Overweight/obesity is the strongest risk factor for endometrial cancer (EC), and weight management can reduce that risk and improve survival. We aimed to establish the differential abilities of intermittent energy restriction (IER) and low-fat diet (LFD), alone and in combination with paclitaxel, to reverse the procancer effects of high-fat diet (HFD)-induced obesity in a mouse model of EC. METHODS: Lkb1 fl/fl p53 fl/fl mice were fed high-fat diet (HFD) or LFD to generate obese and lean phenotypes, respectively...
February 7, 2024: bioRxiv
https://read.qxmd.com/read/38369025/early-regression-index-eri-on-mr-images-as-response-predictor-in-esophageal-cancer-treated-with-neoadjuvant-chemo-radiotherapy-interim-analysis-of-the-prospective-escape-trial
#35
JOURNAL ARTICLE
C Fiorino, D Palumbo, M Mori, G Palazzo, A Pellegrini, L Albarello, A Belardo, C Canevari, A Cossu, A Damascelli, U Elmore, E Mazza, M Pavarini, P Passoni, F Puccetti, N Slim, S Steidler, A Del Vecchio, N G Di Muzio, A Chiti, R Rosati, F De Cobelli
PURPOSE: The early regression index (ERI) predicts treatment response in rectal cancer patients. Aim of current study was to prospectively assess tumor response to neoadjuvant chemo-radiotherapy (nCRT) of locally advanced esophageal cancer using ERI, based on MRI. MATERIAL AND METHODS: From January 2020 to May 2023, 30 patients with esophageal cancer were enrolled in a prospective study (ESCAPE). PET-MRI was performed: i) before nCRT (tpre ); ii) at mid-radiotherapy, tmid ; iii) after nCRT, 2-6 weeks before surgery (tpost ); nCRT delivered 41...
February 16, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38356729/induction-sintilimab-and-chemotherapy-followed-by-concurrent-chemoradiotherapy-for-locally-advanced-esophageal-cancer-a-proof-of-concept-single-arm-multicenter-phase-2-trial
#36
JOURNAL ARTICLE
Dashan Ai, Shengnan Hao, Wenbin Shen, Qibing Wu, Shengjian Zhang, Yun Chen, Qi Liu, Jiaying Deng, Hongcheng Zhu, Ke Chen, Miao Mo, Dayong Gu, Yatian Liu, Zhi Zhang, Guoren Zhou, Jingwen Hu, Zhen Zhang, Jinjun Ye, Kuaile Zhao
BACKGROUND: Concurrent chemoradiotherapy is the standard nonoperative treatment for locally advanced esophageal squamous cell carcinoma. However, local recurrence is still the main failure pattern, accounting for more than half of all treatment failures, indicating that the sensitivity of radiotherapy still needs to be improved. This trial aimed at demonstrating whether PD-1 inhibitors followed by chemoradiotherapy could promote esophageal tumor vascular normalization, alleviate hypoxia, and thus enhance radiosensitivity and improve local control...
March 2024: EClinicalMedicine
https://read.qxmd.com/read/38354746/phase-i-trial-of-apatinib-and-paclitaxel-oxaliplatin-5-fu-levoleucovorin-for-treatment-na%C3%A3-ve-advanced-gastric-cancer
#37
JOURNAL ARTICLE
Shen Zhao, LiYu Su, Feng Huang, Changhua Zhuo, Zaisheng Ye, Hui Li, Yi Yin, Pengqiang Gao, Yong Zhu, Rongbo Lin
Chinese guidelines recommend POF (paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric cancer (AGC). Apatinib can augment the antitumor effect of paclitaxel, oxaliplatin, or fluorouracil in preclinical studies of AGC. A phase I clinical trial was conducted to evaluate the anticancer activity and maximum tolerated dose (MTD) of apatinib plus POF in treatment-naïve patients with AGC and to establish a recommended phase II dose. Participants received escalating doses of daily oral apatinib (250, 375, 500, 625, 750, and 850 mg) plus POF every 2 weeks using a conventional "3 + 3" study design...
February 14, 2024: Cancer Science
https://read.qxmd.com/read/38347177/pd-1-inhibitor-combined-with-albumin-paclitaxel-and-apatinib-as-second-line-treatment-for-patients-with-metastatic-gastric-cancer-a-single-center-single-arm-phase-ii-study
#38
JOURNAL ARTICLE
Miaomiao Gou, Yong Zhang, Zhikuan Wang, Niansong Qian, Guanghai Dai
BACKGROUND: Immune checkpoint inhibitors have been approved for first- and third-line treatment of advanced gastric cancer. However, pembrolizumab alone in the second line did not improve overall survival compared to chemotherapy in the KEYNOTE-061 study. In this study, we aimed to explore the efficacy and safety of a three-drug regimen of PD-1 inhibitor combined with albumin paclitaxel and apatinib (a VEGFR inhibitor) for the second-line treatment of patients with metastatic gastric cancer (mGC)...
February 12, 2024: Investigational New Drugs
https://read.qxmd.com/read/38337591/carboplatin-plus-paclitaxel-in-combination-with-the-histone-deacetylate-inhibitor-vorinostat-in-patients-with-recurrent-platinum-sensitive-ovarian-cancer
#39
JOURNAL ARTICLE
Hanieh Meteran, Anja Ør Knudsen, Trine Lembrecht Jørgensen, Dorte Nielsen, Jørn Herrstedt
Background: This phase II study evaluated the efficacy and safety of the histone deacetylase (HDAC) inhibitor, vorinostat, administered in combination with paclitaxel and carboplatin in patients with platinum sensitive recurrent ovarian cancer. Methods: Women with recurrent platinum-sensitive ovarian, peritoneal, or Fallopian tube carcinoma, a performance status of 0-2, and good overall organ function were eligible. Patients received 6 courses of paclitaxel (175 mg/m2 ) and carboplatin area under the curve (AUC) of 5...
February 3, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38320049/intraperitoneal-carboplatin-for-ovarian-cancer-a-phase-2-3-trial
#40
JOURNAL ARTICLE
Shoji Nagao, Keiichi Fujiwara, Kouji Yamamoto, Hiroshi Tanabe, Aikou Okamoto, Kazuhiro Takehara, Motoaki Saito, Hiroyuki Fujiwara, David S P Tan, Satoshi Yamaguchi, Sosuke Adachi, Akira Kikuchi, Takeshi Hirasawa, Takeshi Yokoi, Tomonori Nagai, Toyomi Sato, Shoji Kamiura, Akira Fujishita, Wong Wai Loong, Karen Chan, Peter Syks, Alexsander Olawaye, Sang-Young Ryu, Hiroyuki Shigeta, Eiji Kondo, Yoshihito Yokoyama, Takashi Matsumoto, Kosei Hasegawa, Takayuki Enomoto
Intraperitoneal Carboplatin for Ovarian CancerThis trial compared intravenous weekly paclitaxel administered with intraperitoneal or intravenous carboplatin. There was a statistically significant increase in progression-free survival in patients with ovarian cancer treated with intraperitoneal versus intravenous carboplatin and paclitaxel, with no difference in overall survival between groups.
May 2023: NEJM Evid
keyword
keyword
163978
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.